Misplaced Pages

Mosliciguat

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Chemical compound
This article is an orphan, as no other articles link to it. Please introduce links to this page from related articles; try the Find link tool for suggestions. (November 2023)
Pharmaceutical compound
Mosliciguat
Clinical data
Other namesBAY 1237592
Legal status
Legal status
  • Investigational
Identifiers
IUPAC name
  • (5S)-5-phenyl]methoxy]phenyl]ethyl]amino]-5,6,7,8-tetrahydroquinoline-2-carboxylic acid
CAS Number
PubChem CID
ChemSpider
UNII
Chemical and physical data
FormulaC41H36ClF3N2O5
Molar mass729.19 g·mol
3D model (JSmol)
SMILES
  • C1C(C2=C(C1)N=C(C=C2)C(=O)O)N(CCC3=CC=C(C=C3)C(=O)O)CCC4=CC=CC=C4OCC5=C(C=C(C=C5)C6=CC=C(C=C6)C(F)(F)F)Cl
InChI
  • InChI=1S/C41H36ClF3N2O5/c42-34-24-30(27-14-16-32(17-15-27)41(43,44)45)12-13-31(34)25-52-38-7-2-1-4-28(38)21-23-47(22-20-26-8-10-29(11-9-26)39(48)49)37-6-3-5-35-33(37)18-19-36(46-35)40(50)51/h1-2,4,7-19,24,37H,3,5-6,20-23,25H2,(H,48,49)(H,50,51)/t37-/m0/s1
  • Key:HFCWZVGKWGOBKV-QNGWXLTQSA-N

Mosliciguat (BAY 1237592) is an inhaled soluble guanylate cyclase activator developed by Bayer for pulmonary arterial hypertension.

References

  1. El-Kersh, Karim; Jalil, Bilal A. (July 2023). "Pulmonary hypertension inhaled therapies: An updated review". The American Journal of the Medical Sciences. 366 (1): 3–15. doi:10.1016/j.amjms.2023.03.002. PMID 36921672. S2CID 257513844.
  2. Friebe, Andreas; Kraehling, Jan R.; Russwurm, Michael; Sandner, Peter; Schmidtko, Achim (August 2023). "The 10th International Conference on cGMP 2022: recent trends in cGMP research and development—meeting report". Naunyn-Schmiedeberg's Archives of Pharmacology. 396 (8): 1669–1686. doi:10.1007/s00210-023-02484-8. PMC 10338386. PMID 37079081.
  3. Auth, Roger; Klinger, James R. (26 October 2023). "Emerging pharmacotherapies for the treatment of pulmonary arterial hypertension". Expert Opinion on Investigational Drugs. 32 (11): 1025–1042. doi:10.1080/13543784.2023.2274439. PMID 37881882. S2CID 264489242.
  4. Becker-Pelster, Eva M.; Hahn, Michael G.; Delbeck, Martina; Dietz, Lisa; Hüser, Jörg; Kopf, Johannes; Kraemer, Thomas; Marquardt, Tobias; Mondritzki, Thomas; Nagelschmitz, Johannes; Nikkho, Sylvia M.; Pires, Philippe V.; Tinel, Hanna; Weimann, Gerrit; Wunder, Frank; Sandner, Peter; Schuhmacher, Joachim; Stasch, Johannes-Peter; Truebel, Hubert K. F. (1 October 2022). "Inhaled mosliciguat (BAY 1237592): targeting pulmonary vasculature via activating apo-sGC". Respiratory Research. 23 (1). doi:10.1186/s12931-022-02189-1. PMC 9526466. PMID 36183104.
Categories: